RecruitingOBSERVATIONAL

Cohort for Monitoring Patients With Venous Thromboembolic Disease

This study is about a common condition where blood clots form in veins, called venous thromboembolic disease. The main goal is to see how new ways of managing patients work. These new ways include special scores that help doctors decide if someone is at high risk of a new clot or bleeding from blood-thinning medicines. The study also looks at the value of regular team meetings where different specialists discuss complex cases. Blood clots can return, and blood thinners, while helpful, can also cause serious side effects like bleeding. So, doctors need to carefully balance these risks. This research aims to understand if these new tools and team discussions help doctors make better decisions for patients, ultimately improving their care.

At a glance

Status

Recruiting

Sponsor

University Hospital, Rouen

Enrolment target

2,000

Start

18 Nov 2019

Estimated completion

01 Jun 2032

Venous Thromboembolic Disease

What is this study about?

Blood clots in your veins, known as venous thromboembolic disease, are quite common. After you've had a clot, there's always a chance it could happen again. Doctors need to figure out this risk, especially if the first clot happened without an obvious reason, like surgery or a long journey.

Taking blood-thinning medication (anticoagulants) helps prevent new clots, but these medicines can also have serious side effects, such as major bleeding. In fact, they are a leading cause of hospital visits for medication-related issues. This means doctors have to carefully weigh up the benefits of preventing future clots against the risks of taking blood thinners. It’s a delicate balance that needs regular checking.

To help doctors with this, new ways have been developed. These include special scores that help predict both the risk of a new clot and the risk of bleeding. There are also regular meetings with a team of different specialists – like blood doctors, general physicians, and cancer specialists – who discuss complex cases. This study aims to see if these prediction scores and team meetings really make a difference in how well patients with blood clots are cared for.

Key takeaways

The study looks at improving care for patients with blood clots.
It evaluates how well new assessment scores work.
It also checks the value of specialist team meetings for complex cases.
The goal is to better balance the risk of new clots and risks from blood-thinning medicine.
It aims to make patient management more effective and safer.

Who may be eligible?

To be considered for this study, you must be an adult aged 18 or over and have had at least one confirmed blood clot. This includes clots in your deep veins (deep vein thrombosis) or in your lungs (pulmonary embolism), as confirmed by medical scans.

You would also need to have been looked after by the Internal Medicine department in a hospital and had your case discussed at their special team meeting about blood clots.

You wouldn't be able to join if your blood clot was in a different part of the body, such as the brain or gut.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Have you been diagnosed with a deep vein clot or a lung clot?
Was your clot confirmed by a scan?
Was your care handled by the Internal Medicine department at a hospital?
Was your case discussed in a specialist thrombosis team meeting?

Answer every question to see your result.

What does participation involve?

The detailed information about what taking part involves is not fully described in this summary. However, generally, studies like this involve observation and review of your medical information, rather than new treatments or specific procedures. This study aims to evaluate the effectiveness of existing tools and processes in managing patients with blood clots. It's likely that researchers would collect information from your medical records related to your blood clot, your treatment, and how different assessment scores were used, as well as if your case was discussed in the specialist team meetings. The total duration of your involvement isn't specified, but it would involve accessing your health information over a period of time.

Potential risks and benefits

There isn't a specific mention of direct benefits or risks for patients participating in this particular study, as it primarily evaluates existing care practices rather than testing new treatments. However, by helping researchers understand which tools and practices work best, the study could indirectly lead to improved care for future patients with blood clots. As with any study, you would always have the right to withdraw your consent and stop participating at any time without affecting your medical care.

Locations (1)

University Hospital of Rouen
Verified postcode
Rouen, France· Recruiting

Common questions

What is venous thromboembolic disease?

It's a medical term for when blood clots form in your veins, most commonly in the legs (DVT) or lungs (pulmonary embolism).

Why is this study being done?

The study wants to find out if new ways of assessing patients, like special scores and team discussions, help doctors better manage blood clots and balance treatment risks.

Will I receive new treatment if I join?

This study is about evaluating current care practices and tools, not testing new medications or treatments directly on patients.

Who is eligible for this study?

Adults over 18 who have had a confirmed blood clot in their veins or lungs, and whose case was managed through specific hospital pathways.

What are blood thinners, and why are they risky?

Blood thinners (anticoagulants) help stop new clots but can also increase the risk of bleeding, which can sometimes be serious.

How to find out more

David DM MALLET, Director

david.mallet@chu-rouen.fr 02 32 88 82 65 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.